Abstract
Currently, there is great interest in identifying safe and effective existing drug therapies for the prevention of coronavirus-2019 (COVID-19). Recently, there is a surge of observational studies, using big data, examining safety and effectiveness of proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) on the risk of new onset COVID-19.1–6 The nature of the disease, limitations of large databases, and use of different methodologic approaches have created unique challenges that might have contributed to contradictory studies addressing this question.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.